🇫🇷 France Country × Condition
quality of life Clinical Trials in France
Active clinical trials for quality of life with research sites in France. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 5 // Recruiting: 5 // Updated: Daily
Total Trials
5
Recruiting Now
5
Country
🇫🇷 France
Active Trials in France (5)
NCT06761196
Recruiting
Quality of Life After Breast Cancer Surgery
Enrollment
1,500 pts
Country
🇫🇷 France
Centre Hospitalier de Colmar
View Trial → NCT06439862
Recruiting
Study of the Quality of Life in School Aged-children With Posterior Urethral Valves
Enrollment
300 pts
Country
🇫🇷 France
Hospices Civils de Lyon
View Trial → NCT05658341
Recruiting
Program of Physical Activity, Nutrition and Supportive to Improve the Quality of Life of Breast Cancer Survivors
Enrollment
160 pts
Country
🇫🇷 France
Siel Bleu
View Trial → NCT05539937
Recruiting
Prospective Evaluation of the Quality of Life of Elderly Patients Undergoing Transfemoral Percutanous Aortic Valve Replacement (TAVI) for the Treatment of Severe Aortic Stenosis.
Enrollment
140 pts
Country
🇫🇷 France
Elsan
View Trial → NCT05414357
Recruiting
Impact of Sleep Disturbance on Cognition and Quality of Life in Breast Cancer
Enrollment
75 pts
Country
🇫🇷 France
Centre Francois Baclesse
View Trial → Frequently Asked Questions
How many quality of life clinical trials are active in France?
There are currently 5 active clinical trials for quality of life with sites in France, of which 5 are actively recruiting patients.
How can I join a quality of life clinical trial in France?
To join a quality of life clinical trial in France, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in France directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are quality of life trials in France?
Active quality of life trials in France span multiple phases. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.